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Abstract Atrial fibrillation and atrial flutter are important risk factors for stroke.
Based on a literature search, pathogenesis of thromboembolism, risk assessment in
patients, efficacy of anticoagulation therapy and its alternatives are discussed.
Special emphasis is put on issues like paroxysmal atrial fibrillation, atrial flutter and
anticoagulation surrounding catheter ablation and cardioversion. A strategy for
anticoagulation around the time of pulmonary vein ablation is suggested.
ª 2005 The European Society of Cardiology. Published by Elsevier Ltd. All rights
reserved.G
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Atrial fibrillation (AF) is an important public health
problem affecting approximately 1% of the general
population. As the frequency of AF increases with
age, it is anticipated that the number of people
with AF will double in the next 25 years [1]. One of
the major goals in treating AF is a reduction in the
incidence of thromboembolic stroke, the most
feared complication of AF. It is estimated that
about 17% of all strokes are caused by AF [2].
* Corresponding author. Tel.: C31 10 463 3991; fax: C31 10
463 4420.
E-mail address: m.f.scholten@erasmusmc.nl (M.F.
Scholten).1099-5129/$30 ª 2005 The European Society of Cardiology. Publis
doi:10.1016/j.eupc.2005.05.012Ischaemic stroke associated with AF is nearly twice
as likely to be fatal as non-AF stroke and the
functional deficits among survivors more severe
[2,3]. In the Framingham Study the risk of stroke in
patients with non-valvular AF was increased five-
fold in comparison with the general population [4].
Valvular AF increases this risk to 17-fold [5].
Atrial fibrillation and
thromboembolism: pathogenesis
and risk assessment
The loss of coordinated atrial contraction is impor-
tant for thrombus formation in patients with AF [6].hed by Elsevier Ltd. All rights reserved.
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atrial appendage (LAA) function are also potentially
at high risk for thromboembolism and might there-
fore require anticoagulation [7]. Approximately
90% of atrial thrombi in non-rheumatic AF are found
in the LAA [8]. Patients less than 60 years of age,
without cardiovascular disease, however, have
a low risk of stroke. Other factors, such as
age and associated cardiovascular disease play
a greater role. Platelet activation, on the other
hand, probably does not play a significant role in
thrombus formation in these patients [9]. Five
large, randomised trials of anticoagulation were
pooled by The Atrial Fibrillation Investigators [10]
and risk factors for stroke were defined. Age was
shown to increase stroke risk by 1.4 per decade.
Other risk factors include previous stroke or tran-
sient ischaemic attack (TIA), hypertension, diabe-
tes mellitus, congestive heart failure, ischaemic or
rheumatic heart disease, prior thrombo-embolism
and female gender (Fig. 1). Patients with rheumatic
heart disease, prosthetic heart valves, prior throm-
boembolism and persistent atrial thrombus de-
tected by transoesophageal echocardiography
(TOE) are considered to be at highest risk [11,12].
Risk stratification using schemes such as the
CHADS2 algorithm can help to quantify the stroke
risk for patients with AF [13] (Table 1). CHADS2 is
a risk assessment algorithm derived from pooled
data. Consistent with ACC/AHA/ESC guidelines [11]
for patients with AF and additional risk factors, any
patient with a CHADS2 score R1 should be consid-
ered for long-term anticoagulation.
Transoesophageal echocardiography (TOE) is
superior to transthoracic echocardiography both
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Figure 1 Relative risk compared with those with
AF, but without these risks. CAD: coronary artery
disease, CHF: congestive cardiac failure, DM: diabetes
mellitus, TIA: transient ischaemic attack. *Adapted from
reference [11].in assessment of left atrial, and left atrial append-
age thrombus, as well as in detection of reduced
flow velocities and spontaneous echo contrast in
the left atrium and left atrial appendage [14]. TOE
is also the method to detect a patent foramen
ovale (PFO), a known cause of paradoxical emboli
causing stroke or transient ischaemic attacks [15].
An association of PFO and septal aneurysms with
stroke exists; a relation with AF is not described.
Patients with AF and complex atherosclerotic
plaques in the aorta have a substantially higher
risk for stroke [16,17].
Efficacy of anticoagulation
Pooled data analysis for oral anticoagulation with
coumadins has shown a relative risk-reduction for
stroke of between 62 and 70% [10,18]. The risk
reductions for stroke were 2.7% per year for
patients without a history of stroke or transient
ischaemic attack, and 8.4% per year for secondary
prevention in patients with a prior stroke [12,19].
Recently, it was established that anticoagulants
should be withheld during the first 14 days in AF
patients with acute ischaemic stroke as the benefit
was completely negated by a higher risk of in-
tracranial bleeding [2].
Level of anticoagulation
Oral anticoagulation has a narrow therapeutic
window. When the international normalized ratio
(INR) is above 2.0 the risk of ischaemic stroke is
low [20]. Above the level of 4.0, however, the risk
of haemorrhagic complications, especially intra-
cranial bleeding, increases significantly [21e23].
For those who continue to have TIAs or strokes
despite a therapeutic INR or those who have a
mechanical heart valve, many experts recommend
a target INR of 2.5 to 3.5 [24]. Risk factors for
major bleeding includes an INR R4.0, advanced
Table 1 The CHADS2 algorithm [1,3]
CHADS2 risk factors Points
C Recent clinical congestive heart failure 1
H Hypertension 1
A Age R75 years 1
D Diabetes mellitus (any form) 1
S History of stroke or transient
ischaemic attack
2
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and unstable INR control [21]. A cohort study
identified three risk factors for haemorrhage in
an elderly population: alcohol abuse, chronic re-
nal insufficiency and previous gastrointestinal
bleeding [27].
Alternatives to standard oral
anticoagulation
Aspirin alone or in combination with low dose
warfarin [28] has been studied. The combination
of aspirin with low dose warfarin does not improve
the risk/benefit ratio [29]. Aspirin alone has
a modest benefit. A meta analysis calculated a risk
reduction of only 21% [30]. The new anti-thrombin
drug ximelagatran has been reported to be a prom-
ising alternative to warfarin [31]. It has been
shown to be equally effective, or at least not
inferior to well controlled warfarin [32]. Further, it
has the advantages of less drug interactions, an
almost immediate anticoagulant action, the ab-
sence of the need for regular dose adjustments
and a lower bleeding risk. However, drug-related
liver injury, led the United States Food and Drug
Administration not to approve its use [32,33].
Fondaparinux and idraparinux are investiga-
tional agents that prevent thrombin formation
[34e37]. They are parenteral, specific, indirect,
factor Xa inhibitors with a mechanism of action
similar to that of heparin.
Because 90% of atrial thrombi in non-rheumatic
AF are found in the left atrial appendage (LAA) [8],
occlusion or resection of the LAA seems an alter-
native to anti-coagulation in the prevention of
thromboembolic events in some patients. A newly
developed device allowing percutaneous LAA oc-
clusion (PLAATO) might be an alternative to oral
anticoagulation for patients with a high thrombo-
embolic risk and a contraindication to anticoagu-
lation [38], and its value is currently being
assessed.
Usage of anticoagulation
Several reports indicate that anticoagulation is
actually underused in AF patients at high risk for
thromboembolic complications [39,40]. Possible
explanations for this underuse are doubts about
the effectiveness of anticoagulation, the fear of
haemorrhagic complications such as intracerebral
bleeding and the limitations of its use, such
as frequent coagulation monitoring and interac-tions with food, alcohol and other drugs. Patient
self-testing and self-management has been shown
to improve the accuracy and quality of oral anti-
coagulation [41,42] and may improve quality of
life.
Special issues
Paroxysmal and persistent AF
In the trials of anticoagulation in AF, between 5
and 25% of the patients had what was labelled at
that time paroxysmal or intermittent AF. In this
group the same risk reduction for stroke was found
as in patients with permanent AF. Patients with
paroxysmal AF and with risk factors for stroke
should therefore be treated with anticoagulation
[43]. The AFFIRM [44] and RACE trials [45] both
compared the benefits of rate in AF control versus
rhythm control (sinus rhythm). In these two stud-
ies, most patients who experienced an ischaemic
stroke either had a suboptimal INR or had discon-
tinued anticoagulation. A very important observa-
tion was that 75% of the patients with an ischaemic
stroke in the rhythm-control group in the AFFIRM
trial were believed to be in sinus rhythm at the
time of the event. Both trials give reason to
reconsider the cessation of anticoagulation after
a successful cardioversion in patients with stroke
risk factors [46].
Atrial flutter
In recent literature, controversy exists about the
need for anticoagulation surrounding cardioversion
of lone atrial flutter [47,48]. The acute and chronic
haemodynamic effects of flutter are not completely
understood. After cardioversion of flutter, the
atria remain stunned for up to 2 weeks, as has
also been shown for AF [49]. The reported in-
cidence of LAA thrombi in patients with lone atrial
flutter varies from 1% [47] to 11% [50]. The
prevalence of LAA thrombi also increases with
age and with lower ejection fraction [51]. Lone
atrial flutter has a similar stroke risk to lone atrial
fibrillation, presumably because it carries a risk for
subsequent development of atrial fibrillation that
is higher than the general population. Further-
more, atrial flutter maybe the result of drug
treatment of AF. In an unselected patient group
with atrial flutter, Seidl et al. [52] found a re-
markably high overall embolic rate of 7%. In this
group the majority of patients were not receiving
oral anticoagulation. Hypertension appeared to be
the only independent risk factor. In patients with
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D
ow
nloaded from
 https://academ
ic.oup.com
/europace/article-abstract/7/5/492/428772 by G
hent U
niversity user on 23 June 2020atrial flutter, markers of a prothrombotic state
(d-dimers and b-thromboglobulin) are not elev-
ated, except for those patients with impaired LAA
function as assessed by TOE. Anticoagulation
should be considered for all patients with atrial
flutter who are older than 65 years of age [53] and
is mandatory in the period before and after
electrical cardioversion [50,54,55].
In conclusion, anticoagulation in atrial flutter
patients should use the same approach as in
patients with atrial fibrillation [56,57].
Anticoagulation and prophylaxis of
thromboembolism in radiofrequency (RF)
ablation of atrial fibrillation and flutter
The treatment of AF entered a new era after
the publication of the landmark observations of
Haı¨ssaguerre et al. [58]. The recognition of the
role of the myocardial sleeves [59] within the
pulmonary veins (PVs) in initiating AF changed
both pathophysiological insights and therapeutic
approaches. Segmental ostial catheter ablation
[60] and left atrial encircling ablation of the PVs
[61] have both been reported to be successful in
the treatment of AF. RF ablation is a highly
effective therapeutic approach in the treatment
of typical isthmus dependent atrial flutter [62].
RF catheter ablation is complicated by throm-
boembolism in about 0.6% of patients [63]. The risk
of stroke from RF ablation may be higher in
paroxysmal AF patients with prior transient ischae-
mic attack [64]. As reflected by elevated plasma
d-dimer levels, RF ablation has a thrombogenic
effect that persists through the first 48 hours after
the procedure [65]. Activation of the coagulation
cascade in RF ablation procedures is not related to
the delivery of RF energy, but is related to the
placement of intravascular catheters and to the
duration of the ablation procedure [66,67]. Fur-
thermore, RF lesions themselves have been shown
to be thrombogenic in acute studies [68]. The risk
of a thromboembolic complication is higher for left
sided ablations (1.8%e2.0%) [63]. By administering
intravenous heparin immediately after introduc-
tion of the venous sheaths, haemostatic activation
is significantly decreased [69]. There is also a sig-
nificant risk for thromboembolism in patients re-
ferred for ablation of typical atrial flutter who
have not been appropriately anticoagulated [70].
Radiofrequency ablation of chronic atrial flutter is
associated with significant left atrial stunning [71].
The NASPE Policy Statement on Catheter Abla-
tion [72] suggests anticoagulation for at least
3 weeks prior to ablation for AF and atrial flutterfor patients who are in these arrhythmias. Discon-
tinuation of anticoagulants 2 to 3 days before the
procedure is possible. For high-risk patients, hep-
arin to cover this period should be considered [72].
TOE shortly before pulmonary vein ablation to
exclude left atrial thrombi is routine in many
clinics [73,74]. We observed an atrial thrombus
on TOE in 9% of patients referred to us for PV
isolation (in press). Generally during left sided
ablation, heparin should be administered, aiming
at an activated clotting time (ACT) of 250e
300 seconds. Higher levels of anticoagulation
(ACTR300 seconds) are used for pulmonary vein
ablations [72]. No clear guideline appears to
exist regarding the use of anticoagulation after a
successful pulmonary vein isolation procedure.
However, it seems logical to continue oral anti-
coagulation for some time after the procedure.
The duration will depend on pre-existing risk
factors. Experienced groups continue anticoagula-
tion therapy at least 3 months after a successful
ablation [73,75,76].
Anticoagulation surrounding cardioversion
for atrial tachyarrhythmias
Thromboembolic events after cardioversion in
atrial tachyarrhythmias have been reported in 1%
to 7% of patients not receiving prophylactic anti-
coagulation [77,78]. Anticoagulation is recommen-
ded for 3 to 4 weeks before and after cardioversion
for patients with AF of unknown duration and for
AF of more than 48 hours duration [11]. A reason-
able alternative strategy is early cardioversion
with a short period of anticoagulation therapy
after exclusion of LA/LAA thrombi with TOE [79].
Anticoagulation in the elderly
Anticoagulation in those over 75 years of age has
been poorly assessed, as this age group was not
well represented in the majority of clinical trials of
anticoagulation. Clearly, age increases the risk of
complications of anticoagulation, but conversely
these patients are also at the highest risk of stroke
[80], so risk assessment and therapy should be
individualised [81].
AF in association with valve prostheses
In patients with bioprosthetic valves and AF,
similar levels of anticoagulation to those men-
tioned above seem adequate. In AF associated
with mechanical valve prostheses, levels of anti-
coagulation recommended are less standardised,
496 M.F. Scholten et al.
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Patient features Antithrombotic therapy Grade of
recommendation
Age !60 years Aspirin (325 mg per day) or no therapy 1
No heart disease (lone AF)
Age !60 years Aspirin (325 mg per day) 1
Heart disease but no risk factors*
Age R60 years Aspirin (325 mg per day) 1
No risk factors*
Age R60 years Oral anticoagulation (INR 2.0e3.0) 12b
With DM or CAD Addition of aspirin daily optional
Age R75 years, especially women Oral anticoagulation (INR approx 2.0) 1
Heart failure Oral anticoagulation (INR 2.0e3.0) 1
EF !0.35
Hypertension
Thyrotoxicosis
Rheumatic heart disease Oral anticoagulation (INR 2.5e3.5 or
higher may be appropriate)
1
Prosthetic heart valve
Prior thromboembolism
Persistent atrial thrombus on TOE
* Risk factors for thrombo-embolism include HF, LV EF !35% and history of hypertension. AF: atrial fibrillation, CAD: coronary
artery disease, DM: diabetes mellitus, EF: ejection fraction, INR: international normalised ratio, LV: left ventricle, TOE:
transoesophageal echocardiography. Adapted from reference [11].rticle-abstract/7/5/492/428772 by G
hent U
niversity user on 23 June 2020but what is clear is that the risks for thromboem-
bolism depend on the type of valve inserted and its
position [82,83]. Accordingly, the target INR for
these patients should be individualised and the
presence or absence of AF has little influence on
this target.
Conclusions
The evidence strongly supports the use of oral
anticoagulation, aiming at an international nor-
malised ratio (INR) between 2 and 3, in patients
with AF who have an average or higher risk of
stroke. This also includes the elderly. Only in
younger patients without additional risk factors is
the use of oral anticoagulation not indicated.
Aspirin is advised by the guidelines (Table 2) for
lower risk patients [11] but a true evaluation in
this patient group is lacking [84]. Paroxysmal AF
and atrial flutter should be treated in the same
way as persistent and permanent forms of AF. For
high-risk patients with a contraindication to anti-
coagulants, a left atrial occluder may be valuable,
and is currently under investigation. Guidelines for
the use of anticoagulation surrounding pulmonary
vein isolation are not yet available, but a high
level of anticoagulation is necessary during the
procedure. It is appropriate to prescribe oralanticoagulation before and to re-initiate it after
the procedure. A covering period with heparin
until the INR reaches the level of 2 is advisable.
It is possible that medical practice will change with
the introduction of new antithrombin drugs and
with further documentation of the efficacy of low
molecular heparin in this area. The initial opti-
mism over the introduction of ximelagatran has
been tempered by criticism on the basis of its side
effects [33].
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